Edward Dyson

Ed counsels public and pre-IPO private companies, investors, entrepreneurs and underwriters on London Stock Exchange, Nasdaq and NYSE capital markets transactions.

• Engagements

  IPOs / Direct Listings / Follow-ons:

  • RegTech Open Project plc on its Main Market Direct Listing
  • Kistos Holdings plc on its AIM Direct Listing
  • Zamaz (now Dispensa Group) plc on its Main Market Direct Listing
  • OKYO Pharma Limited on its Main Market IPO, Nasdaq dual-listing and global follow-ons
  • Codex Acquisitions plc on its Main Market IPO
  • URA Holdings plc on its Main Market IPO
  • Hamak Gold Limited on its Main Market IPO
  • VEF AB on its First North to Nasdaq Stockholm Main Market listing step-up
  • Tiziana Life Sciences Limited on its AIM to Main Market listing step-up, Nasdaq dual-listing, redomiciliation and global follow-ons
  • Supply@ME Capital plc on Main Market follow-ons
  • Mercantile Ports & Logistics Limited on AIM follow-ons
  • Attica Bank S.A. on various Athens Stock Exchange follow-ons
  • AccuStem Sciences Inc. on its demerger and US OTC listing
  • Farmacosmo S.p.A. on its Euronext Growth Milan IPO
  • Heptares Therapeutics Limited on the Nasdaq IPO of Centessa Pharmaceuticals plc
  • Hummingbird Ventures on the Main Market IPO and Standard listing of Deliveroo plc
  • Endava plc on its NYSE IPO
  • Renalytix AI plc on its demerger, AIM IPO and Nasdaq dual-listing
  • the underwriters on the Nasdaq IPOs of Compass Pathways plc, Horizon Discovery plc (aborted), Bicycle Therapeutics plc, Kymab Limited (aborted) and Mereo BioPharma Group plc (aborted)
  • Autolus Therapeutics plc and Nightstar Therapeutics plc on their Nasdaq IPOs
  • Scancell Holdings plc on various AIM follow-ons
  • Realm Therapeutics plc on its direct dual-listing on Nasdaq and subsequent AIM delisting
  • B&M European Value Retail S.A. on its Main Market IPO
  • the underwriters on the Main Market introduction of Metro Bank plc

  M&A / De-SPACs:

  • Sosei Group Corporation on its acquisition of Idorsia’s Japan and APAC (ex-China) pharmaceuticals business
  • Kistos plc on its de-SPAC of Tulip, proposed takeover of Serica Energy plc and acquisition of Mime Petroleum A.S.
  • National World plc on its Main Market IPO, de-SPAC of JPI Media and possible offer for Reach plc
  • Pires Investments plc on its proposed takeover by Tern plc
  • VNV Global on the Nasdaq de-SPACs of Swvl with Queen's Gambit Growth Capital and Gett with Rosecliff Acquisition Corp I
  • Kinnevik on the NYSE de-SPAC of Babylon Health with Alkuri Global Acquisition Corp.
  • Realm Therapeutics plc on its recommended takeover by Essa Pharma Inc. by way of scheme of arrangement
  • RockRose Energy plc on its readmission to listing on the Main Market following the reverse takeover of certain North Sea interests acquired from Marathon Oil
  • MightyHive Inc. on its acquisition by S4 Capital plc

  Private Capital / Strategic Transactions:

  • FOMTECH Limited (Floww) on its Series B financing and strategic partnership to create a global private capital market with London Stock Exchange Group
  • Force Over Mass Capital LLP on partnership matters
  • Metro Africa Xpress Inc. on its Series B financing
  • the financial advisers on a convertible loan note financing by Hawkwing plc
  • Sosei Group Corporation on its collaboration and licensing agreements with Neurocrine Biosciences Inc. and AbbVie Inc.

  Please note: Ed's experience includes that prior to joining Orrick.